evipedia.ai
← Back

Vanadyl Sulfate for Health & Longevity

Evidence Review created on 11/09/2026 using AI4L / Opus 5.5

Also known as: Vanadyl Sulphate, VOSO₄, Vanadium(IV) Oxide Sulfate, Oxovanadium(IV) Sulfate, Vanadium Oxysulfate, Vanadium Oxide Sulfate, Vanadium Sulfate, Vanadyl Monosulfate

Motivation

Vanadyl sulfate is a salt of vanadium, a trace metal present in small amounts in mushrooms, shellfish, black pepper and drinking water. It is sold as an inexpensive dietary supplement and draws interest because, in laboratory work, it imitates part of the signal that insulin sends to cells, which links it to blood-sugar control — a central concern for people aiming to delay age-related metabolic disease.

Interest grew in the 1980s and 1990s, when animal work and small human studies in diabetes examined whether an oral vanadium salt could stand in for, or add to, insulin treatment. In the same period, vanadyl sulfate spread among weight-training athletes hoping for larger muscles. A national scientific body later set an upper daily intake limit for vanadium that sits well below the amounts used in those studies, which keeps safety at the center of the discussion.

This review examines the human, animal and laboratory evidence on vanadyl sulfate for blood-sugar control, body composition and safety, including how the body absorbs, stores and clears it, to set out what is known and unknown for people considering it as part of a longevity strategy.

Benefits - Risks - Protocol - Conclusion

This section lists in-depth narrative reviews that discuss vanadyl sulfate’s clinical history, mechanisms and toxicity.

No item from Rhonda Patrick, Peter Attia, Andrew Huberman, Chris Kresser or Lifespan.io is listed: web and on-site searches found no article, episode or post from these sources that discusses vanadyl sulfate or vanadium in a health context. Life Extension’s only match is a promotional page for a multi-mineral product with a single paragraph on vanadyl sulfate (Life Extension Magazine, July 2000), which falls short of an in-depth discussion.

Grokipedia

Vanadyl sulfate

Covers the compound’s chemistry and industrial uses alongside its investigated insulin-mimetic effects, typical supplement amounts and gastrointestinal and toxicity concerns.

Examine

Vanadium benefits, dosage, and side effects

Examine’s vanadium page, which covers the vanadyl sulfate research, grades the type 2 diabetes evidence and summarizes the 100 mg daily dose used in most studies.

ConsumerLab

No ConsumerLab article on vanadyl sulfate exists.

Systematic Reviews

This section lists systematic reviews and meta-analyses on oral vanadium supplementation and on the health effects of vanadium exposure.

Mechanism of Action

Vanadyl sulfate delivers the vanadyl ion (tetravalent vanadium), which inside the body interconverts with vanadate (pentavalent vanadium), a close structural mimic of phosphate (Cantley 1979).

  • Insulin-signal enhancement: vanadium compounds inhibit protein tyrosine phosphatases, especially PTP1B (protein tyrosine phosphatase 1B, an enzyme that switches off the insulin receptor), prolonging signaling through the PI3K–Akt pathway (the relay that moves glucose transporters to the cell surface) (review: Korbecki 2012).
  • Liver over muscle: in type 2 diabetes, falling fasting glucose tracked reduced liver glucose output, not muscle uptake (Cusi 2001).
  • Competing reading: muscle biopsies showed raised basal insulin-signaling activity but no added effect with insulin, no rise in glycogen synthase (the enzyme that stores glucose as glycogen) activity and no link between serum vanadium and response, pointing to other, unidentified targets (Goldfine 2000).
  • Off-target actions: vanadate also inhibits sodium-potassium ATPase (the membrane pump that keeps sodium out of cells) (Cantley 1979) and generates reactive oxygen species (unstable, cell-damaging oxygen molecules), actions linked to toxicity (review: Korbecki 2012).
  • Pharmacology: selectivity is low across phosphatases. Oral absorption is about 1% or less (Willsky 2013); serum vanadium has an elimination half-time of about 4.6–4.7 days (Willsky 2013). Absorbed vanadium binds albumin and transferrin (the blood’s iron-carrier protein) (Willsky 2001) and accumulates in bone, kidney and liver, persisting for months in rats (Dai 1994). It is handled by redox interconversion (Cantley 1979) and protein binding (Willsky 2001) rather than liver enzyme metabolism; absorbed vanadium is excreted mainly by the kidneys (review: Barceloux 1999).

Historical Context & Evolution

  • Original use: vanadium is mainly an industrial metal for hard steel alloys (review: Barceloux 1999); its compounds were once given as antiseptics, tuberculosis treatments and blood tonics (Cohen 1995).
  • Rediscovery in diabetes: oral vanadate lowered high blood glucose in diabetic rats (Heyliger 1985), prompting human studies; at 100 mg/day for 3 weeks, vanadyl sulfate was reported to lower fasting glucose and improve insulin sensitivity in type 2 diabetes (Cohen 1995), while a dose-ranging study found inconsistent responses and gastrointestinal intolerance (Goldfine 2000).
  • Bodybuilding and mood: athletes adopted doses up to 60 mg/day (review: Barceloux 1999); a controlled trial found no change in body composition (Fawcett 1996). Separately, a psychiatric group proposed excess vanadium as a factor in bipolar illness (Naylor 1981).
  • What changed: the Institute of Medicine (IOM), in its Dietary Reference Intakes (DRI) report, set an upper intake level of 1.8 mg/day of elemental vanadium for adults, based on kidney lesions in rats (IOM DRI report). Development moved to better-absorbed organic complexes, as reviewed by their developers (Thompson 2009), and a systematic review found no trial meeting its quality criteria (Smith 2008).
  • Current standing: opinion is divided — one review judges vanadium treatment of diabetes misplaced (Domingo 2016), another still sees promise as a glucose-control supplement (Crans 2019). The short-term human signals have never been tested in long, adequately sized trials.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: the human evidence consists of uncontrolled before-and-after series or placebo run-in studies of 6–16 participants, and no randomized trial has shown a clinical or validated surrogate benefit.

Medium 🟩 🟩

No benefit reaches Medium: the only randomized placebo-controlled trials of vanadyl sulfate found no effect on insulin sensitivity or body composition, and the positive human findings come from uncontrolled series.

Low 🟩

Glycemic control and insulin sensitivity ⚠️ Conflicted

In type 2 diabetes, fasting glucose fell over 3–6 weeks in uncontrolled series from four groups, each reporting it (Cohen 1995, Boden 1996, Goldfine 2000, Cusi 2001). A randomized prediabetes trial found no insulin-sensitivity change (Jacques-Camarena 2008). Net: short-term glucose lowering appears confined to established diabetes.

Magnitude: After 6 weeks at 150 mg/day, fasting glucose fell from 194 to 155 mg/dL (Cusi 2001; no control group) and HbA1c (glycated hemoglobin, a three-month glucose average) from 8.1% to 7.6% (Cusi 2001; no control group).

Total and LDL (low-density lipoprotein, the main cholesterol carrier linked to artery plaque) cholesterol reduction ⚠️ Conflicted

An uncontrolled diabetes series reported lower total and LDL cholesterol (Cusi 2001); a network meta-analysis ranked vanadium first for total cholesterol at very low certainty (Xia 2023). A randomized athlete trial found no lipid change (Fawcett 1997). Net: an unconfirmed diabetes-only signal.

Magnitude: After 6 weeks at 150 mg/day, total cholesterol fell from 223 to 202 mg/dL (Cusi 2001; no control group) and LDL cholesterol from 141 to 129 mg/dL (Cusi 2001; no control group).

Body composition and strength in resistance training ⚠️ Conflicted

Vanadyl sulfate is marketed to weight-training athletes for lean mass. In a 12-week double-blind trial at 0.5 mg/kg/day, body composition did not change (Fawcett 1996); one leg-extension strength gain may reflect a lower baseline (Fawcett 1996). Net: no demonstrated effect.

Magnitude: No significant treatment effect on body measurements or body composition versus placebo; the only between-group signal was a treatment-by-time interaction (the two groups changed differently over time) in one-repetition-maximum (heaviest single lift) leg extension, and the abstract reports no effect-size figure (Fawcett 1996).

Speculative 🟨

Anticancer activity

Vanadyl sulfate inhibited growth of human lung and prostate cancer cell lines but also harmed non-cancerous cells (Holko 2008). A review describes the basis as cell-culture and preclinical work only (Crans 2019).

Benefit-Modifying Factors

  • Genetic polymorphisms: no study has examined gene variants that modify response to vanadyl sulfate; variants in insulin-signaling genes are plausible but untested modifiers.
  • Baseline glycemia: response appears limited to hyperglycemia (abnormally high blood sugar); 100 mg/day improved insulin sensitivity in type 2 diabetes but not in obese nondiabetic adults (Halberstam 1996), and glucose fell at 150–300 mg/day but not 75 mg/day (Goldfine 2000).
  • Sex: no human sex-specific efficacy data exist; female rats reached higher plasma vanadium than males on vanadyl sulfate (Waidyanatha 2022).
  • Pre-existing conditions: type 2 diabetes showed signals; in type 1 diabetes, one short report found no insulin-action benefit (Aharon 1998) while an uncontrolled 30-month series reported lower insulin needs (Soveid 2013); prediabetes showed none.
  • Age: trials enrolled middle-aged adults; older adults are unstudied, and age-related decline in kidney function may raise vanadium exposure for the same dose.

Potential Risks & Side Effects

High 🟥 🟥 🟥

Gastrointestinal intolerance

Nausea, diarrhea and abdominal cramps are the dose-limiting effects at therapeutic doses, according to a review (Crans 2019). They were reported, mostly in the first week, by Cohen’s group (Cohen 1995) and Boden’s group (Boden 1996), and by Goldfine’s group at 150–300 mg/day (Goldfine 2000). In Fawcett’s placebo-controlled athlete trial, two participants on vanadyl sulfate withdrew for unspecified apparent side effects (Fawcett 1996). Dark stools without bleeding also occurred (Cohen 1995). A systematic review describes gastrointestinal effects as frequent (Smith 2008).

Magnitude: 5 of 6 participants had gastrointestinal symptoms in the first week at 100 mg/day (Cohen 1995; the rate during the placebo periods is not reported), and 6 of 8 participants at 100 mg/day (Boden 1996; the rate during the placebo phase is not reported).

Medium 🟥 🟥

No risk reaches Medium: the only harm seen in a controlled human trial (a triglyceride rise) is contradicted by a larger controlled trial, and the remaining harms rest on animal, cell-culture or environmental-exposure data.

Low 🟥

Triglyceride rise and HDL (high-density lipoprotein, the carrier that removes excess cholesterol) cholesterol reduction ⚠️ Conflicted

In a 4-week randomized trial in 14 adults with prediabetes, 100 mg/day raised triglycerides (Jacques-Camarena 2008); at 300 mg/day, HDL cholesterol fell (Goldfine 2000). A 12-week randomized trial found no lipid change (Fawcett 1997). Net: possible, unconfirmed.

Magnitude: Triglycerides rose from 1.35 to 1.70 mmol/L in the vanadyl sulfate group (Jacques-Camarena 2008); placebo-group values are not reported in the abstract, so the figures are not compared between groups.

Mood destabilization in bipolar disorder

A psychiatric group reported higher plasma vanadium in mania (Dick 1982) and improvement when dietary vanadium was reduced (Naylor 1981). The data concern dietary and endogenous vanadium, not supplements, and come from one research group.

Magnitude: Not quantified in available studies. No study has measured mood outcomes in people taking vanadyl sulfate supplements.

Harm in pregnancy and fetal development

A systematic review of 27 observational studies links environmental vanadium exposure to adverse pregnancy, fetal and reproductive outcomes (Macías-Camacho 2026). Route and form differ from supplements. No safe upper intake could be set for pregnancy (IOM DRI report).

Magnitude: The review reports no pooled outcome figure; it describes harm as depending on vanadium concentration and oxidation state (Macías-Camacho 2026).

Speculative 🟨

Kidney injury from tissue accumulation ⚠️ Conflicted

Rat kidney lesions underpin the upper intake level (IOM DRI report); vanadium persists in rat tissues for months (Dai 1994). A 12-week human trial found no kidney changes (Fawcett 1997). Net: animal-based concern.

Red blood cell changes ⚠️ Conflicted

Mice given vanadyl sulfate in drinking water developed microcytosis (abnormally small red blood cells) (National Toxicology Program 2023). A 12-week human trial found no blood-cell changes (Fawcett 1997). Net: animal-only signal.

Intestinal lining and microbiome changes

Rats and mice developed overgrowth of the small-intestine lining (National Toxicology Program 2023), and 6 months of exposure shifted mouse gut bacteria and bile acids (He 2025). The basis is animal data only.

DNA damage ⚠️ Conflicted

Vanadyl sulfate broke DNA strands in human white blood cells in culture (Wozniak 2004), but caused no mutations in bacteria and no micronuclei (chromosome-damage markers) in rodents (National Toxicology Program 2023). Net: cell-culture signal.

Risk-Modifying Factors

  • Genetic polymorphisms: no variant is known to alter vanadium handling; because vanadium travels on transferrin, iron-handling disorders such as hereditary hemochromatosis (genetic iron overload) are an untested modifier.
  • Baseline kidney function: absorbed vanadium is cleared by the kidneys (review: Barceloux 1999), so reduced kidney function plausibly raises tissue exposure; no human data quantify this.
  • Baseline glucose and medication: people on insulin or sulfonylureas (drugs that make the pancreas release insulin) face added low-blood-sugar risk because vanadyl sulfate lowers glucose in diabetes.
  • Sex: female rats reached higher plasma vanadium than males on vanadyl sulfate (Waidyanatha 2022); human sex differences in side effects are unreported.
  • Pre-existing conditions: pregnancy, bipolar disorder and chronic kidney disease carry the most concern; gastrointestinal disorders may amplify the common bowel side effects.
  • Age: older adults have lower kidney clearance and larger lifetime bone stores, a site of long-term vanadium retention (Dai 1994); no trial enrolled people over about 60.

Key Interactions & Contraindications

Documented interactions:

  • Insulin: in 14 people with type 1 diabetes taking vanadyl sulfate for 30 months, daily insulin fell from 37.2 to 25.8 units (Soveid 2013); consequence: low blood sugar if insulin is not reduced; mitigation: frequent glucose checks and supervised dose adjustment.
  • Sulfonylureas (glyburide, glipizide, glimepiride): participants with type 2 diabetes on diet or sulfonylureas had lower fasting glucose on 100 mg/day, and no hypoglycemia (low blood sugar) symptoms occurred (Cohen 1995); consequence: additive glucose lowering; mitigation: glucose monitoring.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Other glucose-lowering drugs (metformin, pioglitazone, empagliflozin): inferred from additive insulin-like signaling; consequence: lower blood glucose, mainly relevant when insulin or sulfonylureas are also used; mitigation: glucose checks in the first weeks.
  • Cardiac glycosides (heart-rhythm and heart-failure drugs; digoxin): inferred from shared inhibition of sodium-potassium ATPase; consequence: possible heightened digoxin effect and heart-rhythm disturbance; mitigation: combination avoided or digoxin levels checked.
  • Kidney-stressing drugs (NSAIDs, non-steroidal anti-inflammatory over-the-counter pain relievers, such as ibuprofen and naproxen; aminoglycosides, injectable antibiotics, such as gentamicin; lithium): inferred from shared kidney burden; consequence: added kidney injury risk; mitigation: no regular NSAID use, creatinine monitoring.
  • Iron supplements (ferrous sulfate, ferrous bisglycinate): inferred from vanadium binding to transferrin’s iron sites; consequence: altered absorption or transport of either metal; mitigation: doses separated by at least 2 hours.
  • Glucose-lowering supplements (chromium picolinate, berberine, alpha-lipoic acid, cinnamon): inferred from additive glucose lowering; consequence: lower blood glucose than expected; mitigation: one agent added at a time, with glucose monitoring.
  • High-dose vitamin C (ascorbic acid): inferred from vitamin C increasing vanadyl-induced DNA damage in cell culture (Wozniak 2004); consequence: possible added oxidative DNA damage; mitigation: high-dose vitamin C taken at a different time of day.
  • Prolonged fasting or very-low-carbohydrate diets: inferred from additive glucose lowering; consequence: hypoglycemia in people also using insulin or sulfonylureas; mitigation: glucose checks during fasting periods.

Populations who should avoid Vanadyl Sulfate:

  • Pregnant or breastfeeding women: no upper intake level could be set; vanadium should come from food only (IOM DRI report).
  • Children and adolescents (under 19 years): no upper intake level could be set; food sources only (IOM DRI report).
  • People with chronic kidney disease: inferred from renal excretion of vanadium and kidney lesions in rats; no human data.
  • People with bipolar disorder: rests on human data linking higher vanadium to mania (Dick 1982, Naylor 1981); no supplement data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Staying near the upper intake level: total elemental vanadium kept at or below 1.8 mg/day (IOM DRI report), about 6 mg of vanadyl sulfate at 31% vanadium (National Toxicology Program 2023), limits the kidney risk seen in rats.
  • Meals and split doses: taking doses with food and splitting them twice daily, as in trials (Boden 1996), reduces nausea, cramps and diarrhea.
  • Time-limited courses: courses of 4–12 weeks with breaks of equal length limit tissue accumulation, given months-long retention in rat bone and kidney (Dai 1994).
  • Glucose self-monitoring: with insulin or sulfonylureas, daily fasting and pre-meal glucose checks for the first 2–3 weeks prevent hypoglycemia.
  • Kidney and blood checks: creatinine, eGFR (estimated glomerular filtration rate, a kidney-function estimate) and a complete blood count at baseline and after 4–8 weeks detect kidney or red-cell effects early.
  • Lipid recheck: repeat fasting triglyceride and HDL cholesterol measurements after 4–6 weeks detect the adverse lipid shift reported in prediabetes (Jacques-Camarena 2008).
  • Separation from iron and high-dose vitamin C: spacing doses at least 2 hours apart reduces the theoretical transport competition and oxidative DNA-damage risks.

Therapeutic Protocol

Timing, splitting, cycling and titration steps below reflect common practice unless cited.

  • Low-dose supplement regimen: 7.5 mg vanadyl sulfate once daily (Life Extension product page), a manufacturer with a direct financial interest in sales; close to the upper intake level.
  • Upper-intake-level approach: total elemental vanadium of no more than 1.8 mg/day from food, water and supplements (IOM DRI report).
  • Diabetes trial regimen: 100 mg/day for 3 weeks (Cohen 1995), 50 mg twice daily for 4 weeks (Boden 1996), or 150 mg/day for 6 weeks (Cusi 2001); these far exceed the upper intake level.
  • Athletic regimen: 0.5 mg/kg/day for 12 weeks in trials (Fawcett 1996); weight-training athletes reportedly used up to 60 mg/day (review: Barceloux 1999).
  • Avoidance position: a toxicology review judges vanadium treatment of diabetes misplaced (Domingo 2016); this is an alternative to any regimen.
  • Who popularized it: high-dose research came from academic diabetes groups (Cohen 1995, Cusi 2001); athletic use spread through bodybuilding (review: Barceloux 1999); supplement makers market low doses (Life Extension product page).
  • Time of day: with breakfast and dinner to blunt gastrointestinal effects; no study has compared timings.
  • Half-life: serum elimination half-time is about 4.6–4.7 days (Willsky 2013), so levels build over 2–3 weeks and effects persisted 2 weeks after stopping (Cohen 1995).
  • Single versus split dosing: trials split doses twice daily (Boden 1996); low supplement doses are usually taken once daily.
  • Genetic polymorphisms: no pharmacogenetic variant is known to change vanadyl sulfate dosing.
  • Sex: no sex-specific dosing data exist; weight-based dosing (0.5 mg/kg/day; Fawcett 1996) automatically gives lighter people less.
  • Age: for older adults, with lower kidney clearance, common practice is starting at the low end and staying under the upper intake level.
  • Baseline biomarkers: glucose effects appeared only with hyperglycemia, not in nondiabetic adults (Halberstam 1996); people with normal glucose have little measurable target.
  • Pre-existing conditions: type 2 diabetes is the only condition with consistent signals; kidney disease, pregnancy and bipolar disorder argue against use.

Discontinuation & Cycling

  • Short-term use: human data cover 3 weeks to 30 months, mostly under 12 weeks; vanadyl sulfate is not established as a lifelong intervention.
  • Withdrawal effects: none reported; glucose improvements persisted for 2 weeks after stopping (Cohen 1995) and through a 4-week placebo phase (Boden 1996).
  • Tapering: not required; people on insulin or sulfonylureas may need to restore their usual drug doses after stopping.
  • Cycling: no study has tested cycling for efficacy; on-off courses are used to limit tissue accumulation, given months-long retention in rat tissues (Dai 1994).

Sourcing and Quality

  • Compound versus elemental dose: labels may state vanadyl sulfate or elemental vanadium; vanadyl sulfate is about 31% vanadium by weight (National Toxicology Program 2023), and hydrated forms contain less.
  • Third-party testing: USP Verified (United States Pharmacopeia) or NSF Certified (NSF International) marks indicate independent checks of identity, dose and contaminants, relevant because metal salts can carry other heavy metals.
  • Brands: Life Extension sells a 7.5 mg vanadyl sulfate tablet (Life Extension product page); bodybuilding use has involved much higher doses (review: Barceloux 1999).
  • Other forms: organic complexes such as bis(ethylmaltolato)oxovanadium(IV) absorb better but are not marketed (developers’ review: Thompson 2009); vanadium-enriched yeast was used in a recent trial (Ghalichi 2023).

Practical Considerations

  • Time to effect: in type 2 diabetes, fasting glucose fell within 3 weeks (Cohen 1995) to 4 weeks (Boden 1996); HbA1c needs 8–12 weeks to reflect a change.
  • Common pitfalls: confusing compound with elemental dose, exceeding the upper intake level through stacked products, expecting muscle gains, and adding it to insulin without glucose monitoring.
  • Regulatory status: in the US it is sold as a dietary supplement; the FDA (US Food and Drug Administration) does not approve dietary supplements before marketing (FDA dietary supplement Q&A).
  • Funding gap: as an inexpensive, unpatentable salt, vanadyl sulfate offers no commercial sponsor or payer an incentive to fund large trials, which helps explain why decades-old small studies remain the core evidence.
  • Cost: inexpensive and widely available; cost is not a barrier.

Interaction with Foundational Habits

  • Sleep: no direct interaction is known; no study has measured sleep. Indirectly, nighttime hypoglycemia in people on insulin or sulfonylureas could disrupt sleep, so evening glucose checks matter for that group.
  • Nutrition: indirect interaction. Diet supplies only about 6–18 µg/day of vanadium (IOM DRI report), so supplements dominate intake. Taking it with meals eases gastrointestinal effects; separating it from iron supplements avoids theoretical transport competition.
  • Exercise: no blunting or potentiating effect was found in a 12-week training trial, which showed no change in body composition (Fawcett 1996); exercise and vanadyl sulfate both lower glucose, an additive effect relevant only to people on glucose-lowering drugs.
  • Stress management: no interaction is known; no study has measured cortisol or stress responses in people taking vanadyl sulfate.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes the glucose, lipid, kidney and blood-count values against which any change is judged: fasting glucose, HbA1c, a fasting lipid panel, creatinine with eGFR, a complete blood count and ALT (alanine aminotransferase, a liver enzyme).

Ongoing monitoring follows this cadence: fasting glucose self-checks daily for the first 2–3 weeks if insulin or sulfonylureas are used; lipids, creatinine, eGFR, blood count and ALT at 4–8 weeks; HbA1c at 12 weeks; then every 6–12 months during continued use. Success is defined as a fall in fasting glucose or HbA1c without a rise in triglycerides, a fall in HDL cholesterol or a decline in kidney function.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Fasting plasma glucose 70–99 mg/dL (standard reference range) Expected to change; also a safety check for hypoglycemia 8–12 hour fast; morning draw; pair with HbA1c
HbA1c 4.0–5.6% (standard reference range) Expected to change Reflects about 3 months of glucose; recheck no sooner than 8–12 weeks
Total and LDL cholesterol No established target; track change from own baseline Expected to change Fasting lipid panel; same lab each time
Triglycerides No established target; track change from own baseline Safety check: a rise was seen in prediabetes 9–12 hour fast; alcohol in the prior 24 hours can raise values
HDL cholesterol No established target; track change from own baseline Safety check: a fall was seen at 300 mg/day Part of the fasting lipid panel
Serum creatinine and eGFR Creatinine 0.7–1.3 mg/dL (men), 0.6–1.1 mg/dL (women) (standard reference range) Safety check: kidney is the target organ in animals Heavy exercise or large meat meals in the prior 24 hours can raise creatinine
Hemoglobin and MCV Hemoglobin 13.5–17.5 g/dL (men), 12.0–15.5 g/dL (women); MCV 80–100 fL (standard reference range) Safety check: small red cells in mice MCV = mean corpuscular volume, the average red-cell size; part of a complete blood count
ALT 7–55 U/L (standard reference range) Safety check: liver is a vanadium storage site Strenuous exercise in the prior 48 hours can raise values

Qualitative markers:

  • Bowel tolerance (nausea, cramps, stool frequency)
  • Hypoglycemia symptoms (shakiness, sweating, sudden hunger)
  • Energy and fatigue levels
  • Mood stability
  • Tongue or stool discoloration

Emerging Research

  • No ongoing trials: a ClinicalTrials.gov search (November 2026) found no recruiting or active interventional trial of vanadyl sulfate, so no near-term result is expected to change its standing for people optimizing metabolic health.
  • Completed prediabetes trial: NCT00561132 (14 participants, randomized, double-blind; primary endpoint insulin sensitivity) completed in 2004 with no results posted on the registry; its publication found no insulin-sensitivity change and a triglyceride rise (Jacques-Camarena 2008).
  • Organic vanadium complexes: a developers’ review reports that, in a phase IIa trial, 20 mg/day of bis(ethylmaltolato)oxovanadium(IV) for 28 days was associated with lower fasting glucose and HbA1c in 7 people with type 2 diabetes, versus worsening in 2 placebo controls (Thompson 2009); no later-phase results exist, and the compound is not vanadyl sulfate.
  • Low-dose vanadium-enriched yeast: a 12-week randomized trial in 44 obese adults with type 2 diabetes reported improved glucose measures and insulin sensitivity at 0.9 mg/day of vanadium pentoxide in yeast (Ghalichi 2023), a dose within the upper intake level that would strengthen the low-dose case if replicated.
  • Circulating vanadium and diabetes risk: higher serum vanadium predicted lower type 2 diabetes incidence over 14 years (Shen 2025), and higher plasma vanadium was linked to lower odds of gestational diabetes (Li 2022); both are observational.
  • Gut and population safety signals: long-term vanadyl sulfate altered mouse gut bacteria and bile acids (He 2025), and a 2026 review linked environmental vanadium exposure to human harm (Macías-Camacho 2026); both could weaken the safety case.

Conclusion

Vanadyl sulfate is an inexpensive vanadium salt that imitates part of insulin’s signal inside cells. Its appeal for people focused on metabolic health rests on small, short human studies in which people with established type 2 diabetes saw lower blood sugar and, in some reports, lower cholesterol. Those studies lacked proper comparison groups, and the few trials with a placebo comparison found no benefit in people with early blood-sugar problems or in weight-training athletes. For someone with normal blood sugar, there is no human evidence of a measurable gain, and the human studies were too short to address long-term health.

The costs are clearer than the gains. Stomach and bowel upset is common at the doses that lowered blood sugar, and those doses sit far above the upper daily intake limit, which was set because of kidney damage in rats. Vanadium lingers in bone and kidney for months in animals, and animal studies also show changes in red blood cells and the gut lining that have not appeared in short human trials. Concerns in pregnancy and bipolar illness rest on indirect evidence.

The evidence base as a whole is thin, old and short-term. Much of the low-dose positioning comes from supplement sellers with a financial stake in the product. Newer vanadium compounds and low-dose forms have shown early signals, but none has been tested in large or long trials, so vanadyl sulfate’s place in a longevity strategy remains uncertain.

Top - Benefits - Risks - Protocol